Cantitate/Preț
Produs

Kinetics of Enzyme Action – Essential Principles for Drug Hunters

Autor RL Stein
en Limba Engleză Hardback – 4 aug 2011
Few scientists have the knowledge to perform the studies that are necessary to discover and characterize enzyme inhibitors, despite the vested interest the pharmaceutical industry has in this field. Beginning with the most basic principles pertaining to simple, one-substrate enzyme reactions and their inhibitors, and progressing to a thorough treatment of two-substrate enzymes, Kinetics of Enzyme Action: Essential Principles for Drug Hunters provides biochemists, medicinal chemists, and pharmaceutical scientists with numerous case study examples to outline the tools and techniques necessary to perform, understand, and interpret detailed kinetic studies for drug discovery.
Citește tot Restrânge

Preț: 67989 lei

Preț vechi: 71567 lei
-5% Nou

Puncte Express: 1020

Preț estimativ în valută:
13011 13423$ 11012£

Carte tipărită la comandă

Livrare economică 04-18 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780470414118
ISBN-10: 0470414111
Pagini: 320
Dimensiuni: 156 x 234 x 18 mm
Greutate: 0.61 kg
Editura: Wiley
Locul publicării:Hoboken, United States

Public țintă

Medicinal chemists who need to understand basic principles of enzyme kinetics so they are better able to interpret SAR data, scientists, senior scientists and directors in screening and biochemistry departments of biotech and pharmaceutical companies, biochemists, enzymologists, and molecular biologists, graduate students in medicinal chemistry, enzymology, metabolism and pharmacology, and pharma / drug related programs.

Cuprins


Notă biografică

ROSS L. STEIN received his PhD in physical organic chemistry from Indiana University in 1978, after which he conducted post-doctoral research in mechanistic enzymology at the University of Kansas. His career has included positions at Merck, where he headed the Enzymology Department, and ProScript (acquired by Millennium in 1999) as vice president of biochemistry. At ProScript, Dr. Stein was instrumental in the pre-clinical development and co-inventor of the drug VELCADETM, a proteasome inhibitor used to treat multiple myeloma. In 2001, he accepted a position at Harvard Medical School to establish and head the Laboratory for Drug Discovery in Neurodegeneration. Most recently, from 2009-2011, Dr. Stein was vice president of drug discovery at Sirtris Pharmaceuticals.

Descriere

Few scientists have the knowledge to perform the studies that are necessary to discover and characterize enzyme inhibitors, despite the vested interest the pharmaceutical industry has in this field.